Suchergebnisse - "Curtin, Nicola"

PubPharm (6)

1

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

enthalten in: Nature reviews. Clinical oncology | 2019

von Curtin, N. | Drew, Y. | Sharma-Saha, S.

CommentOn: Nature. 2019 Jul;571(7766):576-579. - PMID 31292550

2

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

enthalten in: Cancer discovery | 2017

von de Bono, J. | Ramanathan, R. | Mina, L. | +13

3

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

enthalten in: British journal of cancer | 2016

von Drew, Y. | Ledermann, J. | Hall, G. | +14

CommentIn: Br J Cancer. 2016 Mar 29;114(7):713-5. - PMID 27022824

4

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

enthalten in: Cancer research | 2010

von Issaeva, N. | Thomas, H. | Djureinovic, T. | +18

ErratumIn: Cancer Res. 2010 Oct 1;70(19):7734 Djurenovic, Tatjana [corrected to Djureinovic, Tatjana]

5

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2010

von Mukhopadhyay, A. | Elattar, A. | Cerbinskaite, A. | +7

6

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

enthalten in: Nature | 2005

von Bryant, H. | Schultz, N. | Thomas, H. | +7

ErratumIn: Nature. 2007 May 17;447(7142):346

1
[1]